Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86917 trials found · Page 79 of 4346
-
New injection could transform bleed prevention for kids with haemophilia
Disease control CompletedThis study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. Th…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Immunotherapy showdown: new hope for advanced colon cancer patients in china
Disease control Recruiting nowIn this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New pill challenges IV treatment for deadly fungal infections
Disease control OngoingThe purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Phase: PHASE3 • Sponsor: F2G Biotech GmbH • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
New drug targets genetic kidney disease in major trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
New drug cocktail shows promise in liver cancer battle
Disease control OngoingA global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New combo therapy shows promise in battle against deadly brain tumor
Disease control OngoingThis phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
New shot may keep myeloma away longer after transplant
Disease control OngoingThe purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
New drug combo tested in major lung cancer trial
Disease control CompletedThe primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion s…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New cell therapy tested for leukemia patients out of options
Disease control CompletedThis is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Personalized immune cells target tough liver cancer in new trial
Disease control Recruiting nowThis is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive H…
Phase: PHASE1, PHASE2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Gene therapy shows promise for devastating immune disorder in Long-Term study
Disease control OngoingThis Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the …
Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New IV treatment tested in race against Drug-Resistant malaria
Disease control CompletedThe purpose of this study is to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria. The study also intends to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
New drug combo shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThe main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥1…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Experimental cell therapy targets advanced blood cancer
Disease control TerminatedThis is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
One shot to stop cancer? HPV vaccine study tests Single-Dose power
Prevention OngoingThis phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, main…
Phase: PHASE4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Apr 26, 2026 19:38 UTC
-
Engineered virus teams up with drug to fight deadly brain cancer
Disease control Recruiting nowThis Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Pha…
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
One-Shot gene therapy tested in race against time for babies with devastating disease
Disease control TerminatedPBKR03 is a gene therapy for Krabbe Disease (Globoid cell leukodystrophy) intended to deliver a functional copy of the GALC gene to the brain and peripheral tissues. This study will evaluate the safety, tolerability and efficacy of this treatment by first evaluating two different…
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New hope for early lung cancer: targeted pill may stop return after surgery
Disease control OngoingThis is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
New drug duo aims to keep stage III lung cancer in check
Disease control Recruiting nowThis is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
New Brain-Targeting drug enters final testing for devastating genetic disorder
Disease control OngoingA Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Phase: PHASE3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC